Zhiping Weng

Title: Zhiping Weng: Innovator in Molecular Constructs

Introduction

Zhiping Weng is a prominent inventor based in Wellesley, MA (US). He has made significant contributions to the field of molecular constructs, particularly in the development of modified T-cell receptors (TCRs) for therapeutic applications. With a total of 2 patents, his work focuses on enhancing the specificity and affinity of TCRs for target antigens, which is crucial in cancer treatment and other T-cell mediated pathologies.

Latest Patents

Weng's latest patents include innovative molecular constructs and dual recognition constructs that feature a sequence encoding a TCR affinity weakening motif. These constructs are designed to improve the binding specificity and affinity of modified T-cells compared to non-transformed T-cells. His patents describe methods for transforming cells and utilizing enriched populations of these transformed cells in therapeutic settings. Additionally, he has developed high-affinity variants of the DMF5 TCR, which are intended for the treatment and imaging of cancer in patients.

Career Highlights

Throughout his career, Zhiping Weng has worked at esteemed institutions such as the University of Notre Dame Du Lac and the University of Massachusetts. His research has significantly advanced the understanding of TCR interactions with major histocompatibility complex proteins, leading to potential breakthroughs in cancer therapy.

Collaborations

Weng has collaborated with notable colleagues, including Brian M. Baker and Brian Gregory Pierce. These partnerships have contributed to the development of his innovative approaches in molecular biology and immunotherapy.

Conclusion

Zhiping Weng's contributions to the field of molecular constructs and modified T-cell therapies highlight his role as a leading inventor in the realm of cancer treatment. His innovative patents and collaborative efforts continue to pave the way for advancements in immunotherapy.